Overview
Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction - DOSE Finding Study
Status:
Active, not recruiting
Active, not recruiting
Trial end date:
2023-03-30
2023-03-30
Target enrollment:
0
0
Participant gender:
All
All
Summary
Evaluate the effect of olpasiran administered subcutaneously (SC) compared with placebo, on percent change from baseline in lipoprotein(a) (Lp[a]).Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Amgen
Criteria
Inclusion Criteria:- Age 18 to 80 years
- Lipoprotein (a) > 150 nmol/L
- Evidence of atherosclerotic cardiovascular disease
Exclusion Criteria:
- Severe renal dysfunction
- History or clinical evidence of hepatic dysfunction
- Malignancy within the last 5 years
- Currently receiving, or less than 3 months at Day 1 since receiving > 200 mg/day
Niacin